Pulmonary Sarcoidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Pulmonary sarcoidosis is a complex multisystem disorder with an elusive origin, predominantly affecting young and middle-aged adults and characterized by lung involvement. Approximately 95% of individuals with sarcoidosis will experience some form of pulmonary disease at some point in their lives. The progression of sarcoidosis within the lungs is highly variable, encompassing a spectrum that ranges from spontaneous resolution to advanced fibrocystic disease. While the majority of cases follow a more benign clinical course with a propensity for spontaneous resolution, about 5% of individuals face the development of permanent severe pulmonary dysfunction. This subset of patients contributes significantly to the morbidity and mortality associated with sarcoidosis, with respiratory failure being the leading cause of death in the USA and Europe. Notably, in Japan, cardiac sarcoidosis takes precedence as the primary cause of mortality. Beyond the respiratory system, sarcoidosis can affect various organs, including the liver, spleen, lymph nodes, salivary glands, heart, nervous system, muscles, bones, and others. This widespread involvement underscores the systemic nature of the disease, necessitating a comprehensive approach to diagnosis and management. In the United States, the incidence of sarcoidosis is estimated to range from 5.9 to 6.7 cases per 100,000 population, highlighting its relatively uncommon occurrence. The prevalence of sarcoidosis exhibits a broader range, from fewer than 1 case to 40 cases per 100,000 population. This variability underscores the need for continued research to understand better the factors influencing the development and progression of sarcoidosis and enhance diagnostic and therapeutic strategies for individuals affected by this enigmatic disorder.
Thelansis’s “Pulmonary Sarcoidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Sarcoidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pulmonary Sarcoidosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pulmonary Sarcoidosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment